SEA-BCMA
- Generic Name
- SEA-BCMA
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2115084-53-0
- Unique Ingredient Identifier
- 3C28VJ95EV
- Associated Conditions
- -
- Associated Therapies
- -
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT03582033
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center / University of Iowa, Iowa City, Iowa, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath